Seattle Genetics Inc. (NASDAQ:SGEN) Announce Encouraging Results Of TUKYSA Analyses In HER2 Positive Patients With brain Metastases

Seattle Genetics Inc. (NASDAQ:SGEN) has announced positive results from the intracranial efficacy exploratory analyses of HER2-positive metastatic breast cancer patie4nts that had active or stable metastases in the pivotal HER2CLIMB TUKYSA (tucatinib) study.

The HER2CLIMB study compared a combination of tucatinib with capecitabine and trastuzumab to capecitabine and trastuzumab used alone in HER2-Positive breast cancer with/without brain metastases patients.

TUKSYA showed promise in the reduction of risk of death progression of the disease

Results from the study indicated that TUKSYA addition to capecitabine and trastuzumab in patients having brain metastases slowed brain progression as well as doubled the tumor shrinkage rate in the brain and minimized overall death risk by almost half. The data was consistent in patients that had either active or stable brain metastases. The company presented the data from the 2020 virtual scientific annual meeting of the American Society of Clinical Oncology and published the data in the Clinical Oncology Journal.

The FDA approved TUKSYA in combination with capecitabine and trastuzumab in treating adult patients with metastatic or advanced unresectable HER2-positive breast cancer. This included patients that had previously received more than one anti-HER2-based therapies in the metastatic setting. The company first presented the primary HER2CLIMB results in December last year at the San Antonio Breast Cancer Symposium and published the data in the New England Journal of Medicine.

Encouraging results supporting HER2CLIMB study

Seattle Genetics’ CEO Roger Dansey indicated that the additional analyses and the primary HER2CLIMB analysis indicated that TUKYSA is active for those patients without and with a disease that has reached the brain. The company continues to be encouraging TUKYSA’s remarkable clinical activity in combination with capecitabine and trastuzumab. The CEO added that the company was looking forward to evaluating the potential extra treatment settings as well as tumor types through the current clinical program.

Additional data exploring the effect of TUKYSA in the brain include CNS-PFS, ORR-IC, OS, and response duration analyses in patients with metastatic breast cancer that has spread to the brain.